Sentences with phrase «personalized medicine company»

3DS is a personalized medicine company with a software platform based on the three - dimensional analysis of chromosomal signatures.

«Personalized medicine companies [have been] trying to deal with this for going on 2 years and keep expressing a lot of frustration,» Sauer says.

Transcriptic CEO Max Hodak says his company's services have appealed most to personalized medicine companies, such as De Silva's, and to synthetic biology companies that are tweaking the DNA of microorganisms to make them produce useful substances.

For personalized medicine companies like Optimal Medicine Ltd., the patents are about protecting billions of dollars invested in years of research.

Not exact matches

Traditional lab companies like Quest have also started talking about using blood tests for a personalized medicine approach to the early detection of diseases.

Some has gone to companies like Twist Bioscience, a San Francisco company developing a proprietary synthetic DNA manufacturing process to aid in diagnostics and the production of personalized medicines and sustainable chemicals.

Matt Wanderer's seven - year - old company, based in Madison, Wisconsin, offers personalized medicines to physicians and patients.

Tempus is a precision medicine company that uses a machine learning health care data analytics platform to enable physicians to deliver personalized care to cancer patients.

For aspiring geneticists, the lesson of the two companies» transformations is that genetics is moving into the realm of the practical, with the promise of personalized medicine and pharmacogenomics.

«Young companies trying to get into pharmacogenomics and personalized medicine are facing daunting challenges because of uncertainties with FDA and just the inherent difficulties of trying to change the paradigm to something where side effects are unacceptable,» says Galas.

Hoping to cash in on personalized cancer therapy, a new company called Foundation Medicine — founded in part by genome guru Eric Lander of the Broad Institute — plans to develop tests for genetic glitches in tumors that make them vulnerable to specific drugs, reports the United Kingdom's Times Online.

Also today, the White House announced a batch of projects being launched by some 40 universities, patient groups, companies, and others to promote personalized medicine.

DeCODE Genetics, the Icelandic company that made a name for itself with its personalized medicine work before running into a financial mud pit, tried to be optimistic today about its future.

Companies are increasingly moving towards niche drugs based on personalized medicine, says Kaitin — although there are exceptions.

One of the core beliefs at ISB is that medicine will become more and more personalized, with people sequencing their own genes and pharmaceutical companies developing drugs for groups with certain genetic characteristics.

A Mexican geneticist who studied in the United States, she's the CEO of Código 46, a new company in Cuernavaca that plans to offer genotyping services for personalized medicine to Mexican clients starting next month.

The case highlights concerns that a network of individual gene patents could threaten the future of personalized medicine and whole - genome sequencing by blocking companies and clinicians from reporting a patient's genetic risk factors for different diseases.

Consequently, the safest investment in the ESC field may be «something where you're an enabler of the technology» by providing the raw tools and ingredients for ESC research, says Steve Brozak, an analyst with WBB Securities in San Diego, Calif. «The time frame [for ESCs] is now for drug discovery, soon for personalized medicine, and decades for therapeutic use,» adds Bob Palay, chairman and CEO of Cellular Dynamics International (CDI), a biotech company working with ESCs in Madison, Wisc..

This isn't to say the beginnings of personalized medicine haven't arrived — some biotechnology companies already offer individual DNA reports that provide people with information about disease risks and possible drug interactions based on a DNA sample [source: Pathway Genomics].

She was the founder and CEO of two innovative healthcare companies: DNA Direct, the first medical genetics company to focus on bringing personalized medicine to the consumer, and Direct Medical Knowledge, a consumer health web site unique for its content depth and innovative search interface.

She also helped develop the company's tailored therapeutics and personalized medicine strategy.

Invivoscribe Technologies Inc. is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, cutting - edge reagents, tests, and bioinformatics tools to advance the fields of personalized molecular diagnostics ® and personalized molecular medicine.

SAN DIEGO, CA --(Globe Newswire — Nov 7, 2017)- Invivoscribe ® Technologies Inc., a global company with decades of experience providing clonality and biomarker test solutions for the fields of oncology and personalized molecular medicine ®, announces the release of the Research Use Only (RUO) version of its LymphoTrack ® TRB Assay for the Illumina MiSeq ® platform.

In 2013 she formed Biome Healthcare with J. Craig Venter which was later acquired by «Human Longevity Inc.» a company dedicated to link genomic and clinical data with the goal of facilitating personalized medicine.

SAN DIEGO, March 28, 2017 (GLOBE NEWSWIRE)-- Invivoscribe ® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics ®, and personalized molecular medicine ®, reports that its next - generation sequencing (NGS) LymphoTrack ® Assay kits are being used by its LabPMM ® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T - cells (CAR - T) and engineered T - cell receptors in peripheral blood of subjects in support of immuno - therapeutic drug development and treatment regimen development for both hematologic and solid tumors.

In 2013, together with colleagues, she founded the company «Human Longevity Inc.», which links genomic and clinical data to further the goal of personalized medicine.

March 16, 2017 Tempus and University of Chicago collaborate on groundbreaking breast cancer project UChicago Medicine and technology company Tempus are partnering to personalize breast cancer treatment by analyzing medical data.

Silvia Binder is the founder of The Binder Institute for Personalized Medicine in Southern Germany and the CEO of the Ondamed Companies in New York and Germany.

With his company, Advanced BioCell, Mr. Quateman has developed a comprehensive process for engaging, guiding and educating and servicing clients in the rapidly growing field of systems - based personalized functional medicine, the leading edge of the wellness industry.

Proponents of personalized medicine were thankful for several developments that show this trend is picking up speed: CVS followed Medco's example in expanding pharmacogenomic testing, while biotech and pharma companies, as well as the National Cancer Institute, stepped up their investment in the field.